Ten Capital Wealth Advisors’s Summit Therapeutics SMMT Stock Holding History

Ten Capital Wealth Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,000	Closed	-$3.5K	–	468
2023 Q1	$3.5K	Hold	2,000	–	–	﹤0.01%	440
2022 Q4	$8.5K	Hold	2,000	–	–	﹤0.01%	328
2022 Q3	$2K	Hold	2,000	–	–	﹤0.01%	493
2022 Q2	$2K	Hold	2,000	–	–	﹤0.01%	404
2022 Q1	$5K	Buy	+2,000	New	+$5.04K	﹤0.01%	377

Other funds holding SMMT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Ten Capital Wealth Advisors's SMMT Position: Q2 2023 in Review

Ten Capital Wealth Advisors sold out of Summit Therapeutics (SMMT) in Q2 2023, closing a stake of 2,000 shares — an estimated $3.5K sold.

Ten Capital Wealth Advisors first reported a position in SMMT in Q1 2022 and held it in 5 quarters. The position peaked at $8.5K in Q4 2022. 100 funds tracked by Wall St. Rank hold SMMT as of Q2 2023.

Ten Capital Wealth Advisors reported no remaining Summit Therapeutics position as of Q2 2023 after selling out during the quarter.
Ten Capital Wealth Advisors sold 2,000 Summit Therapeutics shares in Q2 2023, an estimated $3.5K.
Ten Capital Wealth Advisors first reported a position in Summit Therapeutics in Q1 2022 and held it in 5 quarters.
Ten Capital Wealth Advisors's Summit Therapeutics position peaked at $8.5K in Q4 2022.
100 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2023.

Based on Ten Capital Wealth Advisors's 13F filing for Q2 2023, filed 31 Jul 2023.